QUESTIONS ABOUT COVID-19?
AbbVie is working closely with the World Health Organization (WHO) and global health authorities to respond to the needs of patients impacted by COVID-19. For more information about what AbbVie is doing to address the global COVID-19 crisis, please visit https://www.abbvie.com/coronavirus.html.
As the number of COVID-19 cases continue to rise around the world, questions are being raised about the impact it may have on the global supply of medicine. AbbVie continues to closely monitor manufacturing and supply chain resources around the world and we do not anticipate any disruption to our SKYRIZI supply for patients as a result of COVID-19.
AbbVie has not studied the use of SKYRIZI (risankizumab-rzaa) in patients with COVID-19 nor in patients at risk of contracting COVID-19.
Management of SKYRIZI therapy is at the discretion of the patient and health care professional, taking into consideration the risks vs. benefits for each patient. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves.
SKYRIZI may increase the risk of infections. Please refer to the full
SKYRIZI Prescribing Information for additional information.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Important Safety Information
SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.
In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis (TB)
Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.
Most common (≥1 %) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
Please see Full Prescribing Information.